The atypical cyclin CNTD2 promotes colon cancer cell proliferation and migration

• Published in: Scientific reports Vol. 8; no. 1; pp. 11797 - 12
• Main Authors: Sánchez-Botet, Abril, Gasa, Laura, Quandt, Eva, Hernández-Ortega, Sara, Jiménez, Javier, Mezquita, Pau, Carrasco-García, Miquel Àngel, Kron, Stephen J., Vidal, August, Villanueva, Alberto, Ribeiro, Mariana P. C., Clotet, Josep
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 07.08.2018; Nature Publishing Group
• Subjects: 13; 13/44; 13/51; 13/89; 64; 64/60; 692/4028/67/1504/1885/1393; 692/4028/67/395; 82; 82/1; Cell migration; Cell proliferation; Ciclines; Colon cancer; Colorectal cancer; Colorectal carcinoma; Cyclins; Càncer colorectal; Humanities and Social Sciences; Migració cel·lular; multidisciplinary; Proliferació cel·lular; Science; Science (multidisciplinary); Tumors; Xenografts
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-30307-x

Colorectal cancer (CRC) is one of the most common cancers worldwide, with 8–10% of these tumours presenting a BRAF (V600E) mutation. Cyclins are known oncogenes deregulated in many cancers, but the role of the new subfamily of atypical cyclins remains elusive. Here we have performed a systematic analysis of the protein expression levels of eight atypical cyclins in human CRC tumours and several cell lines, and found that CNTD2 is significantly upregulated in CRC tissue compared to the adjacent normal one. CNTD2 overexpression in CRC cell lines increases their proliferation capacity and migration, as well as spheroid formation capacity and anchorage-independent growth. Moreover, CNTD2 increases tumour growth in vivo on xenograft models of CRC with wild-type BRAF . Accordingly, CNTD2 downregulation significantly diminished the proliferation of wild-type BRAF CRC cells, suggesting that CNTD2 may represent a new prognostic factor and a promising drug target in the management of CRC.